Zoetis Inc. (NYSE:ZTS) Shares Sold by Sarasin & Partners LLP

Sarasin & Partners LLP lessened its position in shares of Zoetis Inc. (NYSE:ZTS) by 8.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,059,588 shares of the company’s stock after selling 194,002 shares during the quarter. Zoetis makes up about 3.8% of Sarasin & Partners LLP’s investment portfolio, making the stock its 7th largest position. Sarasin & Partners LLP owned 0.45% of Zoetis worth $402,402,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Brevan Howard Capital Management LP boosted its holdings in Zoetis by 7.9% during the fourth quarter. Brevan Howard Capital Management LP now owns 6,608 shares of the company’s stock valued at $1,304,000 after purchasing an additional 482 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Zoetis by 31.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock valued at $2,707,262,000 after buying an additional 3,244,074 shares in the last quarter. Peloton Wealth Strategists grew its position in Zoetis by 5.5% in the fourth quarter. Peloton Wealth Strategists now owns 9,839 shares of the company’s stock valued at $1,942,000 after acquiring an additional 509 shares during the period. Able Wealth Management LLC acquired a new position in Zoetis during the fourth quarter worth $552,000. Finally, GLOBALT Investments LLC GA acquired a new stake in shares of Zoetis in the 4th quarter valued at $2,296,000. 92.80% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

ZTS has been the topic of several analyst reports. JPMorgan Chase & Co. upped their target price on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday. Argus raised shares of Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Piper Sandler lifted their target price on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. BTIG Research increased their price target on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Finally, Stifel Nicolaus lifted their price objective on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, September 18th. Ten analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $221.44.

Zoetis Trading Up 1.1 %

Shares of ZTS traded up $2.08 during trading hours on Friday, hitting $192.36. 104,277 shares of the stock traded hands, compared to its average volume of 2,541,932. The business has a fifty day moving average of $187.88 and a 200-day moving average of $175.97. The firm has a market capitalization of $87.15 billion, a PE ratio of 37.29, a price-to-earnings-growth ratio of 2.95 and a beta of 0.89. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The company had revenue of $2.36 billion for the quarter, compared to analyst estimates of $2.31 billion. During the same quarter last year, the firm earned $1.41 EPS. The company’s revenue for the quarter was up 8.3% on a year-over-year basis. Analysts expect that Zoetis Inc. will post 5.83 EPS for the current year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.